The Xandar Kardian stand at CES 2026
Newsroom

News, press releases and the press kit.

Journalists: a person answers. Facts are checked against the registrations and the published studies before we say them.

News and press releases
2026Award
iF Design Award 2026A third iF award for the XK300 family, after the CT series in 2023 and the XK300-H in 2024.
2025Recognition
Deloitte Technology Fast 50, CanadaNamed among the country’s fastest-growing technology companies.
1 August 2025Press release
Iris IoT and Xandar Kardian partner to bring ambient health monitoring to the UKA distribution partnership taking the XK300 into care homes and homes across the United Kingdom.
March 2025Regulatory
Health Canada licence for the XK300Medical device licence 112865.
5 November 2024Award
Special mention in TIME Best Inventions 2024The XK300-H, the company’s second appearance on the list.
4 October 2024Award
Gold at the McKnight’s Tech Awards 2024Telehealth category, with Dr. Noel Serrano, medical director of skilled-nursing facilities in California.
15 July 2024Press release
Validation Institute certifies the XK300 outcome claimIndependent validation: the readings preceded 75.6% of hospital transfers in a 201-patient study.
9 May 2024Coverage
Regina police install radar monitoring in cellsCBC News.
17 April 2024Award
Red Dot Design Award 2024 for the XK300-HJudged by a jury of 39 from 20 countries.
21 March 2024Coverage
Correctional facilities in the UK and Ireland deploying new radar technologyCorrectional News.
1 March 2024Award
iF Design Award 2024 for the XK300-H
28 February 2024Press release
Xandar Kardian and The Lava Group partner for the UK and IrelandCustodial health monitoring through Lava’s Tephra suite.
22 January 2024Press release
Xandar Kardian and Ceragem announce an integrated partnershipRadar sensing inside Ceragem’s home wellness products, Korea.
18 December 2023Press release
Partnership with GT Global ServicesCustodial monitoring for Canadian police services.
8 December 2023Press release
Fast Company Next Big Things in Tech and three 2024 CES Innovation AwardsDigital Health category; fifteen CES awards over four years.
August 2023Press release
Fifty deployments with healthcare facility partners across the United States
3 July 2023Coverage
Using radar to monitor body vibrationsAgeTech Collaborative from AARP.
2023Interview
The American Heart Association interviews Xandar Kardian on contactless monitoring

Earlier releases, from 2018 to 2023, are available on request from the press contact.

Awards and recognition

Recognised for the design and for the outcome.

TIME Best Inventions2022 and 2024
Validation InstituteHealth outcomes validation, 2024
CES Innovation AwardsFifteen awards over four years, Digital Health
iF Design Award2023, 2024 and 2026
Red DotDesign Award 2024
Deloitte Technology Fast 50Canada, 2025
Health Value Awards2025
UpLink, World Economic ForumInnovator, healthy ageing

Also: McKnight’s Tech Awards Gold 2024; Fast Company Next Big Things in Tech 2023; the WHO Compendium of innovative health technologies for low-resource settings, 2024.

Featured in Fierce Biotech Fast Company Healthcare IT Today AgeTech Collaborative from AARP American Heart Association Correctional News Lexington Herald Leader
Press kit

Boilerplate, logos and approved images.

Boilerplate

Xandar Kardian Inc. is a medical technology company founded in 2017 and headquartered in Toronto, with research, development and manufacturing in Seoul and an office in New York. Its XK300 radar sensor measures heart rate and breathing rate through the air, from the wall or ceiling, with nothing worn, and is FDA-cleared (510(k) K202464, 2021) and registered in Canada, Australia, Singapore and Thailand. The XK300 is used on hospital wards, in long-term care, in home health and remote patient monitoring, and in correctional and behavioural health; more than 49,000 people have been monitored to date. Kardian, the company’s consumer line, brings the same radar science to the home. Xandar Kardian is privately held.

Facts to check against
  • Founded 2017. Delaware corporation, headquartered in Toronto.
  • FDA 510(k) K202464, April 2021. Class II, prescription.
  • ISO 13485 under MDSAP, certificate 0187405.
  • 37 journal publications; 36 patents.
  • Outcome validation: Validation Institute, 2024, 75.6% of hospital transfers, 201 patients.
  • Sam Yang, Chief Executive Officer and Co-Founder.

Images may be used in editorial coverage of Xandar Kardian with credit. For anything else, please ask.